Fall Clinical Dermatology Conference

Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed randomized trial in hidradenitis suppurativa at Fall Clinical 2026.

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy trial in psoriasis.

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

At Fall Clinical 2026, Angela Fitch, MD, discussed GLP-1 prescribing by dermatologists and the metabolic and inflammatory link to psoriasis.

Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026.

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib.

At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism, and ongoing clinical trials at his trial center.

In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.

Which vitiligo patients need oral vs topical JAK inhibitors? Iltefat Hamzavi, MD, shares his approach at Fall Clinical 2026.

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research.

Todd Schlesinger, MD, highlighted the new photodynamic therapy indication for superficial basal cell carcinoma, immunotherapy options for cutaneous squamous cell carcinoma, and sequential actinic keratosis therapy at Fall Clinical 2026.

Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.

At Fall Clinical 2026, Aaron Farberg, MD, reviewed gene expression profiling in atopic dermatitis and melanoma, and the Ameluz plus PDT approval for superficial basal cell carcinoma.

At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls

At Fall Clinical 2026, Jennifer Hsiao, MD, discussed patient preference, comorbidities, and access guide HS treatment selection.

Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin.

At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.

At Fall Clinical 2026, Shannon Trotter, DO, reviews locally advanced and metastatic cutaneous squamous cell carcinoma, immune checkpoint inhibitors, and proposed Medicare cuts affecting skin cancer care.

Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.

Christopher Bunick, MD, PhD, presented long-term safety data for JAK inhibitors upadacitinib and abrocitinib in atopic dermatitis at Fall Clinical 2026.

Jennifer Hsiao, MD, explains how defining HS treatment response improves adherence and success.

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

At Fall Clinical 2026, Raj Chovatiya, MD, PhD, MSCI, urged clinicians to understand the data and consider systemic therapy in atopic dermatitis.

Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.